+34 620 10 75 37info@nanbiosis.com

Singular

Singular

U23-S03. Micromanipulation and microinjection (Onsite&Remote) OUTSTANDING

Micromanipulation and microinjection oocyte; IMSI system; Embryo biopsy systems (Saturn Laser); vision systems of the mitotic spindle (Oosight system)

Read More

U23-S02. Embryo culture media viability studies (Onsite&Remote) OUTSTANDING

Embryo selection; collection and transport for the study in animal models

Read More

U23-S01. In vitro fertilisation studies and embryo culture media viability (Onsite&Remote) OUTSTANDING

Biopsed of blastomeres; oocyte microinjection; Oocyte and embryo cryopreservation; Implantation Studies

Read More

U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING

Preclinical efficacy assays in
Preclinical evaluation of efficacy according to European Directives; In vivo models for the pilot feasibility; Biocompatibility. Animal models of human diseases: diabetes, obesity, hypercholesterolemia, hypertriglyceridemia, acute and chronic myocardial infarction, prostatic hyperplasia, ulcers, pleural adhesions, constrictive pericarditis, and abdominal aortic aneurysm among other; Animal species: rodents, rabbits, dogs, cats, pigs and sheep. Creation of different pathologies: oncological, cardiovascular, ophthalmology, transplants, assisted reproduction, cell therapy, etc.
Efficacy and safety of medical devices and biomaterials. Efficacy and toxicity studies of new molecules and pharmaceutical forms.
Murine model embryo tranfers; intracytoplasmic microinjection, oocyte vitrification, measurement and analysis of samples of Natural Killer cells (NK), seminogram and semen studies.

Read More

U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING

The service includes de use of singular equipment for optical in vivo imaging (IVIS® Spectrum and Macrofluo) for the acquisition and quantification of bioluminescent and/or fluorescent images in vitro, in vivo or ex vivo.

Quantification services, as well as support on the analysis of obtained images by specialized personnel is also included.

Read More

U20-S02. Animal models in oncology (Remote) OUTSTANDING

The unit/platform has strong background in oncology and counts with different type of cancer mouse models, all of them monitorable by means of bioluminescence imaging. They include subcutaneous models in a great variety of cancer types (prostate, colon, breast, pancreas, kidney, etc.) and also orthtopic and experimental metastasismodels.

The unit/platform can also set-up and validate novel xenograft models upon request.

 List of available models

  • Subcutaneous models (different cell lines and cancer types)
  • Orthotopic models:
    • Intraprostatic
    • Intramammary (i.m.f.p.)
    • Stereotactic
    • Ceccum
    • Intrapulmonar
  • Experimental metastases:
    • Intracardiac (bone metastases)
    • Intravenous (lung metastases)
    • Intraportal (liver metastases)
  • Spontaneous metastases
Read More

U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING

Planing, execution and interpretation of in vivo assays requirestime and expertise. At this unit, we give consultancy serviceson  preclinical model design, support and advice for research projects, including selection and use of the appropriate imaging system and evaluation and interpretation of the data obtained.

Read More

U20-S04. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING

The unit/platform is specialized in oncology and lysosomal storages diseases, and several animal models are available for this type of diseases.

However, we are experienced in developing new efficacy models for testing novel nanomaterials, carriers and therapeutica compounds. Please contact us to see how we can help you in your research Project.

Read More

U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING

Potential target toxicity of new nanomaterials and drug delivery systems has to be carefully evaluated to support further clinical assays.  At U20 we can design, perform and evaluate all type of toxicological studies, including those toxicity analyses performed along with efficacy studiestomore specifically designed long-term or short-term toxicity assays.

Specifically, we provide full services of anatomical pathology, from sample preparation, inclusion, section and staining to anatomopathological evaluation.

Read More

U19-S01. Preclinical studies

Preclinical studies

This service is responsible for conducting regulatory preclinical studies for the pharmaceutical industry and interested companies. Among the studies that can be carried out are: in vivo toxicity studies, local and systemic tolerance and efficacy studies. Pharmacokinetic studies, dosage studies of test products and biocompatibility studies of new drugs and medical devices are also performed.

Customer benefits

These studies are carried out under strict quality regulations, certified with ISO-9001 and Good Laboratory Practices (GLP), quality standards that allow the production of high-precision results.
Therefore, preclinical studies can be carried out in compliance with the strict guidelines of regulatory agencies, ensuring the reliability and traceability of all results and tests carried out in their different services.

Target customer

The services offered may be of interest to different companies and laboratories that work within the pharmaceutical industry. Companies whose objective is to test possible candidates for molecules, drugs or medical devices.

References

  1. J Bote, et al. Novel ex-vivo database of a murine model of colorectal cancer using optical coherence tomography. Surg Endosc (2022) 36:S325–S674
  2. V Lucas-Cava, et al. Prostatic artery occlusion: Initial findings on pathophysiological response in a canine prostate model. Translational Andrology and Urology. Transl Androl Urol 2022.
  3. Soria F, et al. Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization-assessment in ureteral stricture endourological treatment in animal model. Transl Androl Urol. 2021 Apr;10(4):1700-1710.
  4. Baez-Díaz C, et al. Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model. Sci Rep. 2020 Apr 28;10(1):7166.
  5. Moreno-Lobato, B, et al. Use of nanomedicine in preclinical wound healing studies. FarmaJournal; Salamanca T 4, N.º 1, (Feb 2019): 178.
  6. Picado Román, N, et al. Drugs most used in experimental animals in a Research Center. FarmaJournal; Salamanca T 4, N.º 1, (Feb 2019): 236.
  7. Moreno-Lobato B, et al. Analytical Validation Study of Hematological Parameters under Good Laboratory Practice Regulations in Different Laboratory Animal Species. Thromb Haemost Res. 2019; 3(1): 1018.
  8. Ballestín A, et al. A Pre-clinical Rat Model for the Study of Ischemia reperfusion Injury in Reconstructive Microsurgery. J Vis Exp. 2019 Nov 8;(153).
  9. R Blázquez , et al. Altered hematological, biochemical and immunological parameters in a porcine myocardial infarction model: predictive biomarkers for the severity of myocardial infarction. Veterinary Immunology and Immunopathology 205 (2018) 49–57.
  10. Vela FJ, et al. Evaluation of antigen-induced synovitis in a porcine model: Immunological, arthroscopic and kinetic studies. BMC Vet Res. 2017. Apr 7;13(1):93.
Read More